MX2022002977A - Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. - Google Patents
Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3.Info
- Publication number
- MX2022002977A MX2022002977A MX2022002977A MX2022002977A MX2022002977A MX 2022002977 A MX2022002977 A MX 2022002977A MX 2022002977 A MX2022002977 A MX 2022002977A MX 2022002977 A MX2022002977 A MX 2022002977A MX 2022002977 A MX2022002977 A MX 2022002977A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- prevention
- treatment
- binding molecules
- her3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1913079.8A GB201913079D0 (en) | 2019-09-11 | 2019-09-11 | Treatment and prevention of cancer using her3 antigen-binding molecules |
| PCT/EP2020/075319 WO2021048274A1 (en) | 2019-09-11 | 2020-09-10 | Treatment and prevention of cancer using her3 antigen-binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002977A true MX2022002977A (es) | 2022-07-12 |
Family
ID=68241208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002977A MX2022002977A (es) | 2019-09-11 | 2020-09-10 | Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11208498B2 (https=) |
| EP (2) | EP3818086B1 (https=) |
| JP (2) | JP7708741B2 (https=) |
| KR (1) | KR20220086554A (https=) |
| CN (2) | CN116059347A (https=) |
| AU (1) | AU2020347473A1 (https=) |
| BR (1) | BR112022004474A8 (https=) |
| CA (1) | CA3149853A1 (https=) |
| DK (1) | DK3818086T3 (https=) |
| ES (1) | ES2896921T3 (https=) |
| GB (1) | GB201913079D0 (https=) |
| MX (1) | MX2022002977A (https=) |
| PL (1) | PL3818086T3 (https=) |
| PT (1) | PT3818086T (https=) |
| TW (1) | TWI883044B (https=) |
| WO (1) | WO2021048274A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3433273T (pt) | 2016-03-25 | 2022-02-21 | Biomunex Pharmaceuticals | Moléculas de ligação a cd38 e pd-l1 |
| SG11201809316XA (en) * | 2016-04-28 | 2018-11-29 | Biomunex Pharmaceuticals | Bispecific antibodies targeting egfr and her2 |
| KR20240125061A (ko) | 2017-03-27 | 2024-08-19 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| CN114790462B (zh) * | 2021-01-25 | 2023-10-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向bcma的嵌合抗原受体及其应用 |
| CN112961865B (zh) * | 2021-02-22 | 2023-06-02 | 广西大学 | 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用 |
| EP4304636A1 (en) * | 2021-03-11 | 2024-01-17 | Elevation Oncology, Inc. | Dosage and administration of anti-erbb3 (her3) monoclonal antibodies to treat tumors associated with neuregulin 1 (nrg1) gene fusions |
| TW202313987A (zh) * | 2021-06-03 | 2023-04-01 | 荷蘭商美勒斯公司 | 用於測定nrg1融合多核苷酸的液態檢體測定法 |
| JP2024523001A (ja) * | 2021-06-03 | 2024-06-25 | メルス ナムローゼ フェンノートシャップ | 新たなｎｒｇ１融合体、融合接合部及びそれらを検出するための方法 |
| GB202108449D0 (en) | 2021-06-14 | 2021-07-28 | Hummingbird Bioscience Holdings Pte Ltd | Cells expressing her3 antigen-binding molecules |
| US20250136712A1 (en) | 2021-08-13 | 2025-05-01 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| JP2024536719A (ja) * | 2021-09-03 | 2024-10-08 | キャンサー・リサーチ・テクノロジー・リミテッド | Ｈｅｒ３抗原結合性分子を使用したがんの処置および予防 |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| US20240117030A1 (en) * | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| WO2024121163A1 (en) | 2022-12-06 | 2024-06-13 | Cancer Research Technology Limited | Combination of 10d1f and an androgen inhibitor for treatment and prevention of cancers |
| CN120417924A (zh) | 2022-12-07 | 2025-08-01 | 蜂鸟生物科技私人有限公司 | 治疗和预防癌症的组合疗法 |
| WO2024147097A1 (en) | 2023-01-03 | 2024-07-11 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| EP4687972A1 (en) | 2023-04-06 | 2026-02-11 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3 antigen-binding molecules |
| KR20260022498A (ko) | 2023-04-14 | 2026-02-19 | 허밍버드 바이오사이언스 피티이. 엘티디. | 암의 치료 및 예방을 위한 조합물 |
| WO2025057173A2 (en) * | 2023-09-14 | 2025-03-20 | B.G. Negev Technologies And Applications Ltd. | Ligand-based chimeric antigen receptors and uses thereof |
| WO2025056781A1 (en) | 2023-09-15 | 2025-03-20 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using her3-binding molecules |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| MY152068A (en) * | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| EP2571901B1 (en) * | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Biological materials related to her3 |
| CN104105709A (zh) * | 2011-12-05 | 2014-10-15 | 诺华股份有限公司 | 抗her3的结构域ii的表皮生长因子受体3(her3)抗体 |
| US20130259867A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
| WO2014182970A1 (en) * | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
| EP3085781A1 (en) | 2013-12-19 | 2016-10-26 | National Cancer Center | Novel fusion gene as factor responsible for stomach cancer |
| WO2016059602A2 (en) * | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3679063A4 (en) | 2017-09-08 | 2021-06-02 | The Regents of The University of Colorado, A Body Corporate | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OR PREVENTION OF HER-CONTROLLED DRUG-RESISTANT CANCER |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| WO2019185164A1 (en) * | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
-
2019
- 2019-09-11 GB GBGB1913079.8A patent/GB201913079D0/en not_active Ceased
-
2020
- 2020-09-10 AU AU2020347473A patent/AU2020347473A1/en active Pending
- 2020-09-10 CN CN202211117480.0A patent/CN116059347A/zh active Pending
- 2020-09-10 PT PT207805722T patent/PT3818086T/pt unknown
- 2020-09-10 EP EP20780572.2A patent/EP3818086B1/en active Active
- 2020-09-10 EP EP21180956.1A patent/EP3943509A1/en active Pending
- 2020-09-10 JP JP2022516173A patent/JP7708741B2/ja active Active
- 2020-09-10 KR KR1020227011181A patent/KR20220086554A/ko active Pending
- 2020-09-10 BR BR112022004474A patent/BR112022004474A8/pt unknown
- 2020-09-10 MX MX2022002977A patent/MX2022002977A/es unknown
- 2020-09-10 CA CA3149853A patent/CA3149853A1/en active Pending
- 2020-09-10 ES ES20780572T patent/ES2896921T3/es active Active
- 2020-09-10 WO PCT/EP2020/075319 patent/WO2021048274A1/en not_active Ceased
- 2020-09-10 DK DK20780572.2T patent/DK3818086T3/da active
- 2020-09-10 PL PL20780572T patent/PL3818086T3/pl unknown
- 2020-09-10 TW TW109131184A patent/TWI883044B/zh active
- 2020-09-10 CN CN202080009114.6A patent/CN113347994B/zh active Active
-
2021
- 2021-01-20 US US17/153,705 patent/US11208498B2/en active Active
- 2021-11-24 US US17/535,313 patent/US20220153870A1/en active Pending
-
2025
- 2025-07-02 JP JP2025112447A patent/JP2025143396A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220086554A (ko) | 2022-06-23 |
| TWI883044B (zh) | 2025-05-11 |
| PT3818086T (pt) | 2021-10-26 |
| CN116059347A (zh) | 2023-05-05 |
| JP7708741B2 (ja) | 2025-07-15 |
| PL3818086T3 (pl) | 2022-03-14 |
| US20210155712A1 (en) | 2021-05-27 |
| GB201913079D0 (en) | 2019-10-23 |
| US11208498B2 (en) | 2021-12-28 |
| CN113347994B (zh) | 2022-09-23 |
| BR112022004474A2 (pt) | 2022-06-21 |
| CA3149853A1 (en) | 2021-03-18 |
| DK3818086T3 (da) | 2021-10-04 |
| TW202123926A (zh) | 2021-07-01 |
| EP3943509A1 (en) | 2022-01-26 |
| AU2020347473A1 (en) | 2022-03-31 |
| BR112022004474A8 (pt) | 2023-01-17 |
| ES2896921T3 (es) | 2022-02-28 |
| JP2025143396A (ja) | 2025-10-01 |
| EP3818086B1 (en) | 2021-08-04 |
| WO2021048274A1 (en) | 2021-03-18 |
| JP2022548057A (ja) | 2022-11-16 |
| EP3818086A1 (en) | 2021-05-12 |
| US20220153870A1 (en) | 2022-05-19 |
| CN113347994A (zh) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002977A (es) | Tratamiento y prevencion del cancer usando moleculas de union a antigeno her3. | |
| CL2024001607A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| EA202091846A1 (ru) | Соединения с активностью, индуцирующей ферроптоз, и способы их применения | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| JOP20200082B1 (ar) | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| BR112017018234A2 (pt) | inibidores de pd-1 / pd-l1 para o tratamento de câncer | |
| MY209831A (en) | Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BR112022024483A2 (pt) | Métodos para tratar mieloma múltiplo | |
| BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
| BRPI0908276B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| BR112014008819A8 (pt) | Métodos para o tratamento de síndrome de vazamento vascular e câncer | |
| DOP2019000019A (es) | Metodos para tratar el cancer de prostata | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| MX2023014069A (es) | Composiciones y métodos para el tratamiento del cáncer de próstata. | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| CO2023017973A2 (es) | Trampas de ligando del factor de crecimiento transformante βeta para el tratamiento de enfermedades | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| BR112023026111A2 (pt) | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo | |
| JOP20220294A1 (ar) | علاجات سرطان البروستاتا مع توليفات من أسيتات أبيراتيرون ونيراباريب | |
| EA202190226A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ |